Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ioanna Gouni-Berthold , Veronica Alexander , Qingqing Yang , Eunju Hurh , Elisabeth Steinhagen-Thiessen , Patrick Moriarty , Stephen Hughes , Daniel Gaudet , Robert Hegele , Louis St L O'Dea , Erik Stroes , Sotirios Tsimikas , Joseph Witztum , Abhay Agarwal , Christie Ballantyne , Seth Baum , Jean Bergeron , Eric Bruckert , Richard Burdick , Manuel Castro-Cabezas , Mark Cervi , Clinton Corder , Robert Dufour , Cecil Murray Farrington , Gordon Francis , Lawrence Galitz , Steven Hamstead , Linda Hemphill , Cynthia Huffman , Basil Issa , Ulrich Julius , John Kane , Michel Krempf , Steven Martin , James Powell , Richard Shultzaberger , Craig Thompson , Letitia Thompson-Hargrave , Peter Toth , Traci Turner , Rene Valero (1) , Bruno Verges , Frank Visseren , Pankaj Vyas , Alberto Yataco

1 C2VN - Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research

Domains: Life Sciences [q-bio]

Ioanna Gouni-Berthold, Veronica Alexander, Qingqing Yang, Eunju Hurh, Elisabeth Steinhagen-Thiessen, et al.. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Diabetes & Endocrinology , 2021, 9 (5), pp.264-275. ⟨10.1016/S2213-8587(21)00046-2⟩. ⟨hal-03654674⟩